Keyword
in
Collection
Date
to
Houston Voice, No. 903, February 13, 1998
File 018
Citation
MLA
APA
Chicago/Turabian
Houston Voice, No. 903, February 13, 1998 - File 018. 1998-02-13. University of Houston Libraries. University of Houston Digital Library. Web. September 21, 2020. https://digital.lib.uh.edu/collection/montrose/item/1305/show/1285.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(1998-02-13). Houston Voice, No. 903, February 13, 1998 - File 018. Montrose Voice. University of Houston Libraries. Retrieved from https://digital.lib.uh.edu/collection/montrose/item/1305/show/1285

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, No. 903, February 13, 1998 - File 018, 1998-02-13, Montrose Voice, University of Houston Libraries, accessed September 21, 2020, https://digital.lib.uh.edu/collection/montrose/item/1305/show/1285.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, No. 903, February 13, 1998
Contributor
  • Michelak, J. C.
  • Murphy, Terry
Publisher Window Media
Date February 13, 1998
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Collection
  • University of Houston Libraries Special Collections
  • LGBT Research Collection
  • Montrose Voice
Rights In Copyright
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 018
Transcript COVER STORY and "clarifying" the fact that he had not taken a position on domestic partner benefits. "When I read that [statement] and put it together with statements he made on the campaign trail," said Parker. "That translates to me that the mayor supports domestic partners benefits, but he doesn't want to state that publicly." Speculation on motives As to what effect the anti-gay public opinion effort mighl have, activist Hill expressed bemusement about the apparent goal of "the ring leaders of the effort to somehow get a referenda regarding this matter. I don't know what they are going lo do unless they change the charter, which changes the exist ing structure of Houston City Government." Since the City Charter grants the mayor the power to issue such an order without any input from the City Council or the general public, the only way to prevent him from doing so is to ammend lhe City Charter in a public referendum. "And that's a much broader issue than executive policy not to discriminate," Hill said. He said he believes Brown and supporters of the executive order currently have a strong strategic advantage. "If we can fight this thing out on a structural level as opposed to din- gling wilh thc issue, it's a dead cinch win," he said. "It's not a well-thought out threat. Of course, [executive order opponents] are not the most politically sophisticated people." Hill said he did not foresee Brown being persuaded by an onslaught of anti-gay public opinion to table the issue by not signing the order. "Brown has nothing to fear from city council," Hill said. "You remember whai Clinton did when he first got inlo office with gays in the military. People were screaming and they pissed and moaned; for all intents and purposes, that thing blew up in his face. .And what happened? He was re-elected four years later. So, the lesson is: The time for Mayor Brown lo do this is now. Everyone has short political memories." MAINE/, from page 1 state were devastated by ice storms that knocked out electrical power to large portions of the state. Maine lawmakers enacted a bill last spring adding sexual orientation to the protected classifications in Maine's 25-year-old human rights act. The measure was designed to bar discrimination against gays and lesbians in employment, housing, public accommodations and credit. But a successful people's veto drive, as provided for in the state constitution, blocked implementation of the new law. Repeal advocates led by conservative Christian groups collected more than 58.000 signatures to put the issue on state ballots. "It took 20 years for this bill to get Ihrough the Legislature and 1 think the time will come when people will recognize that this is a fair and just way to proceed, but a majority of the people who voted today don'l agree." King said. King added, however, that he did not think the matter should be -a M 300 mp lofeWtr. Viramune (nevirapine)CQO Simple maintenance dose: one 200 mg tablet twice daily BRIEF SI WARNING VIRAMUNE' INEV1RAPINE) IS INDICATED I0H USE IN COMBINATION WITH NUCLEOSIDE ANALOGUES FDR llll ir-i'MIY rip mi\ ' iN'-i AnjUS'.VW ■■:.. HiEliUlKllW.1 AMU OF IMMUNOLOGIC DHEHrORAIffl 'illilNO'iiiMM; BASH lN.\W;*SS*i' :h*NGE5 IN SlrHROGAII [WOl'ITS IN : ■ ■ - ■ .'..-• ■ . v ' ■ ICA. TRIALS EVALUATING THE EFFECT Of VHMMUHE- WITH NU**i0SIDt ANALOGUES ON THE CLINICAL PROGRESSION Of HIV. I INFECTION SUCH AS THE INCIDENCE Of OPPORTUNISTIC INFECTIONS OR SUR- THE DURATION OF BENEEIT FROM ANTIRETROVIRAL THERAPY MAY BE LIMITED ALTERATION OF ANTI w-rsioviRAi rmRAPitssH'iiji:*!*! : <..■ hfrf: sfass mws' on *ccupc iwili patients ARE RECEIVING VIRAMUNE- RESISTANT VIRUS EMERGES RAPIOLY AND UNIFORMLY WHEN VIRAMUNE' IS ADMINISTERED AS MONOTHERAPY THEREFORE. VIRAMUNE" SHOULD ALWAYS BE ADMINISTERED IN COMBINATION WITH AT LEAST ONE ADDITIONAL ANTIRETROVIRAL AGENT VlfWMUNf* HAS BEEN ASSOCIATED WITH SEVERE RASH. WHICH IN SOME CASES HAVE BEEN LIFE- THREATENING WHEN SEVERE RASH OCCURS. VIRAMUNE' MUST BE DISCONTINUED CONTRAINDICATIONS: VIRAMUNE* is cortrMutated period utiHI IM rash das resolved met DOSAGE ANO ADMINISTRATION) PRECAUTIONS: G»n»*.WIifin-idminnltiiiigVIRAMUNE' as pariofanantirMroviralheatmenl regimen. the complete product information tor each therapeutic component should be consulted belore inrliahon re eitensivefy an evaluated m palients wild with caution in these pal lent While newrap I by Dm irnei and nevio eliminated by the kidney, the pharmacokinetics ol nevirapine have n either hepatic oi lenal dysfunction Therefore. VIRAMUNE* Should be populations Abnormal liver hincbon tests have been leported with VIRAMUNE*". some in Hie tirst lew weeks of therapy, including cases of hepatitis. VIRAMUNE' admmisliation should be interrupted in palients experiencing moderate or severe liver lunclion test ahnoimalilies until liver lunclion tests return to baseline valutrs. VIRAMUNE* trealmenl should be permanently discontinued if liver function abnormalities recur on read- On* InHitctltna Although clinical sludies have not been conducted, induction of CYP3A by nevirapine may result in lowei plasma concentrabons Ol '■' metabolized by CYP3A {see CLINICAL PHARMACOLOGY) Thus, if a pahenl has been stabilized on a dosage regimen lor a drug metabolized by CYP3A. and begins treatment with VIRAMUNE'. dose adiusi ments may be necessary RrtampttVRilaOiilm Thete aie insuHicienl dala lo assess whether dose adiuslmenls are necessary whsn nevirapine and rifampin or rifabutin are coadministered Therefore these drugs should only be used m combination rt clearly indicated and with careful monitoring Protease Inhibitors Nevirapine may decrease plasma cor:.Da ■ Ion Therefore. until clinical dala are available thai evaluate lhe need for dose adiuslmenls. ihese drugs should not be admnislBred concomilanlty wtth VIRAMUNE* contraceptives' Neiir^ine nay decrease pusme concajrttratioiis oforaTcorrtraieptives (also oilier hormonal comraceWves); thereto™, these drugs should nol be admmslered concomrtantty with VIRAMUNE- HHomamm le- Pttomts: Palients should be informed thai VIRAMUNE* is not a cure for HIV-1 miedion. and ttut they may conbnue lo mpenence illnesses associated with advanced HIV-1 infection. Including oppor- turns**: mfccftwis Treatment with VtRAA*UN"=" las not been shown to rebut* the incidence or frequency ol such (Messes, and patients should be ad**! to remain iindei tlwcaie of aohysician when using VIRAMUNP Patients should be informed lhal Ihe long-term eflects ol ol HIV-1 to oH promptly nmmtf lie* physician of any nth The ma|onty ol rashes assooalod with VIRAMUNE" occur within the first 6 weeks ol inflation ol therapy Therefore pawn's should be monitored caieluey for Ihe appearance ol rash during this period Patients should be mst-ucted thai dose escalation is nol to occur it any lash occurs during lhe two-week lead-in dosing period. until Hie rash resolves Any patienl experiencing severe rash or a rash accompanied by ecu " - swehng. muscle or-anf aches, or Patients should be informed fo take VIRAMUNE" eveiy day as prescribed Palienls should not alter the dose withoul consulting their Ooctor If a dose is missed, patients should take the next dose as soon as possible However, it a dose is skipped, the patient should not double the next dose VIRAMUNE* may in Israel with some drugs, therefore, patienis should be advised to report fo Iheir doctor ihe use ol any other medications Patients should be instructed thai oral contraceptives and olher hormonal methods of birth control should not be used as a method ol contraception in women taking VIRAMUNE' tutu. WnUfmnr, ImpiltmtM ¥ FtdlWy: Long-term carcinogenicity studies of nevirapine are currently in progress In genetic toxicology assays, nevirapine showed no evidence of mutagenic of clastogentt activity in i battery ol in vitro and in vivo assays including microbial assays for gene initiation (Ames Salmonella strains and f cort). mammalian call gene mutation assays ICHOHGPflT). cyfogenelic assays using a Chinese tumstt ovary a* line and a mouse bone marrow micronucleus assay totowmg oral administration In reproductive toxicology studies, evidence ol impaired slem-ic exposure, based or al dose ol VIRAMUNE" PrnmiiKy Piegnancy Category C No observable teratogenicity was detected ir performed in pregnanl rals and rabhils In rats a signta*-' "" ::'■■■..". nmwhii'i* ..'i*nii e.prr.uie ,ippini>niile:> '>»■, n:3 :al dose The maietnal and developmental no-observable-effect lei il syitenw Bipn ure:. jpotox 1I1V1 eiimvaienl I jppionmatery Sir., Inqlii'i ■■ilii.incy only if ol5Bhc m breasl milk Consistent with lhe recommendation by lhe US Public Health Service Centers for Disease Control and Prevenlion that HIV-infected mothers not breast-feed then inlanls to avoid risking postnatal transmission ol HIV. mothers should discontinue nursing if Ihey are receiving VIRAMUNE PiMtlric list: Safety and ellectrveness of VIRAMUNE in pediatric palients have nol been established VIRAMUNE has Men studied in iwo open-label uncontrolled trials (Bl 882. Bl 8921 m 37 HIV-1-infected pediatric patients wilh a median age ol 09 years (range: 01 lo IS years) who were healed tor a median duration of 20.7 months Seven patients developed rashes while receiving VIRAMUNE' In an ongoing conliolled tnal ol VIRAMUNE' combination fherapy in HIV-1-infected pediatric palienls (ACTG 245). one of approximately 268 pahents heated wnh VIRAMUNE experienced Stevens-Johnson syndrome Because Ihere are no Data on multi-dose pharmacokinetics m children, no recommendation on dosing can be made Based on single-dose pharmacokinetics in 9 HIV-1-infected pediatric palienls (age 9 mos to 14 years) who were adminislered nevirapine m a suspension lormulalion it appears tMt oral clearance is approximately 2-fold greater in children when compared lo adults ADVERSE REACTIONS: The mosi lrt«juently reporieO adverse events related to VIRAMUNE" therapy were rash, fever nausea headache, and abnoimal liver function tests The ma-or clinical toxicity ol VIRAMUNE" is rash with VIRAMUNE -attributable lash occumng in 17* of - -""is Thirty-seven perceni of patients treated ■; I ill ttimof 7 6% of VIRAMUNE*-tn us eruptions, wilh or wil ZDV,odI ui ZDV atone liable Ii Severe or lite Threatening rash occurret patienis compared with 1 2% of patients healed in the control groups RasMs aie usually mild lo moderate, maculopapulai erythematous cuta pruritus Kn ■:■ * MM TMmaiority of se.. . _. first 28 days ol treatment. 25% ol Ihe patients with severe rashes required hospilalialion. and or patient leaurreu singiul iriarrn-nMin An ;,..:■■(■':. ■eciiveied Over.ill . . .>! latentx Oasconlmo. VIRAMUNE- due to rash Tattle l: Percentage ol palienls with rashes in controlled Mats' ;.:,-'■■ Bl 1037 LU-1011 combine: :wia 'I.-..!'. KM ZDV .OS KiW*. m NV ■-."'. zdv m CONTROL n 197 201 30 3D 25 24 25? 255 Rash events of al LM-amj-JtaiMO »« 23. W 26 7% in 32 0'r l« 37 3% 200% Grade 1 111 4 mil events, all causality a.n 15', ',!'■■ 0% 8 0=a 0% w% 12* ie first 14 days followed by one 200 mg (a Table 2 lists ireatmenl*related clinical adverse events lhat occurred in patients receiving VIRAMUNE" m ACTG 241 and in Trials Bl 1037 and 611011 Table 2 Cnmparativ* Incidence ol Selected Orug Related Evenls in Comrolled TrBS ACTG 241 Trial Bl 103 and Bi 1011 Mi-.-.4..- b M seventies tht\m ZDV-dtH NVP.ZDV ZDV alone Number ol patents 197 201 55 30 Overt nafcreeol 31% 23% 42% 33% Rash B 2 20 3 fever 3 3 II 3 Nausea 5 4 9 3 Headache 3 3 I] 0 Diarrhea 2 2 0 0 Abdominal pain 1 2 2 0 Ulcerative slomalilis 0 0 J 0 Penpheral Neinopalhv 0 2 0 0 Fj'afSWesu 1 0 2 0 Myalgia 1 0 2 7 Hepalnrs 1 0 4 0 ti Wurtoty ibftwi mWm « Tat* 3: Percentage ol palients wuh marked laboratory abno DtU combined for conliolled trials ACTG 241. Bl 1037 & Bl 1011 VIRAMUNE' n=252 n,255 Decreased Hg .<t 0 g«L) Decreased platelets frJO.OOO'mnii Decreased neutrophiK (<7Wnm') Blnod chamndry Increased AL1 (.250 LWi Increased AST (,250 UA) Increased GGT MSD U.1) Increased total Wrumn 025 mgAIL} 12% 09 24 '20% DJ 102 19 24 M 0VEHDOSAGE: TMre is no known antidote lor VIRAMUNE" overdosage No ac lae were reported for one palwnt who ingested 800 mg of VIRAMUNE" for one CAUTION FEDERAL lAW PROHIBITS DISPEr-JSING WITHOUT PRESCRIPTION fMlrjiMM' 1. Data oh file. Roxane respectrveiy in .!■■■■ H: cent If Roxane l!**j Laboratories. Inc. brought back before the Legislature "anytime in the immediate future." Said King: "1 don't think a referendum closes the door forever, but I think the people of Maine have made their views known and that should be respected." Elizabeth Birch, executive director of the Human Rights Campaign, said the vote reflected the need for a federal law to protect homosexuals and lesbians against discrimination. "I know that the people of Maine care about this issue. I know that they believe in basic fairness for their gay citizens, and we will never, ever give up." she said. "We will go back to the Legislature, we'll go back to the peo- pie." The campaign leading up to Tuesday's vote was relatively low key. with limited media advertising and only scattered debates between representatives of the two sides. January ice storms that disrupted utility service in most of the state also effectively muffled political activity for weeks- Just over two years ago, Maine voters turned down a proposal by anti- gay-rights activists to freeze existing protections in the state human rights act. The proposal lost by 53 percent to 47 percent. AUSTIN/ from page 5 the time," Bethune said. It also accepts female ministers, a controversial move In Baptist circles. Four years ago. University Baptist made headlines when it ordained a gay deacon. The Austin Baptist Association responded by removing the church from Its membership. AUSTIN AREA UPDATE by Steve Labinski Gay rowers makes their mark in Dallas event Two members of Row Team Austin (RTA) claimed victories at the Southwest Ergometer Amateur Tournament (S.W.E.A.T.) in Dallas Feb. 7. In this dry land event, rowers showed their strength and endurance on indoor ergometers designed to simulate the power needed to row on water. More than 1 OO competitors, including UT Crew members, participated, representing age categories from collegiate on up. RTA's Paul Hemmer captured first place in the 40-49 age division for heavy-weights with a time of 6:30 for the 2000 meter power piece. RTA Coordinator Steve Onken. with a time of 6:57. not only took first place in the 40-49 age division for light-weight competitors, but also beat all lightweight limes in the 30-39 age bracket as well. More impressively, both men placed sixth among all ages in the event in their weight divisions. "I'm excited to see such great representation for our team at this event, lt sets us off to a great start for our training season." said RTA Coach Matt Diefenbach. Row Team Austin is a group of over forty rowers who will be heading to Amsterdam to represent Austin In .Amsterdam for the Gay Games in August Other events: Lesbian Gay/Right Lobby (LGRL) will hold a fund-raiser from 6-8 p.m. Tues., Feb. 24 at The Speakeasy. 412 D Congress Ave, Proceeds benefit LGRL and the CALKIN Fund. Tickets are $15. Call (512) 474-5475. AIDS Services of Austin will hold a fund-raiser at the Austin Music Hall on Sat.. Feb. 15. Call Kirk Rice at RAGE
File Name uhlib_31485329_n903_017.jpg